Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Nutanix Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Nutanix Inc trades at $74.63 (market cap $19.78B). The key difference: Nutanix Inc is the larger of the two by market cap, and Halozyme Therapeutics Inc. Common Stock is more actively traded (2,179,278 versus 1,717,619). Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Nutanix Inc for 17 Days on average.
| HALO | NTNX | |
|---|---|---|
Market Cap | $12.58B | $19.78B |
Volume | 2,179,278 | 1,717,619 |
Sector | Health | Technology |
52-Week High | $115.22 | $74.63 |
52-Week Low | $61.63 | $34.41 |
Typical Hold Time | 1 Days | 17 Days |
Enterprise Value | $14.49B | $18.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nutanix (NTNX) trades at $73.08, down 0.46% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $76.11. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.60 surpassing the $0.49 expectation. Revenue growth is robust, projected to rise from $2.54 billion in 2025 to $2.9 billion in 2026, while net income margin expanded significantly to 52.81%.
The outlook remains positive driven by strong execution, external storage partnerships, and AI growth initiatives, though high valuation multiples like EV/EBITDA of 46.22 and negative ROE of -395.76% pose risks. Investor sentiment is buoyed by recent Gartner recognitions and earnings beats, but supply chain pressures and competitive threats require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
